Hey guys, so in the pathway for the basal ganglia, First Aid states that dopamine activate D1 receptors to stimulate movement and it activates D2 receptors to inhibit movement. However, some of the drugs that are used to treat Parkinsons (ropinirole) are D2 receptor agonists, so wouldn't that worsen Parkinsons disease symptoms since you are stimulating a receptor that decreases movement in a patient who already suffers from bradykinesia?